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ABSTRACT Corneal transplantation serves as a reproducible and simple surgical model to study mechanisms regu-
lating immunity and angiogenesis. The simplicity of the model allows for systematic analysis of different mechanisms 
involved in immune and angiogenic privilege and their failures. This protocol describes how to induce neovessels and 
inflammation in an actively regulated avascular and immune-privileged site. This involves placing intra-stromal corneal 
sutures for two weeks, disrupting the privileges, and performing corneal transplantation subsequently. Privileged and 
non-privileged recipient responses to donor cornea can be compared to identify key immunological mechanisms that 
underlie angiogenesis and graft rejection. This protocol can also be adapted to the growing repertoire of genetic models 
available in the mouse, and is a valuable tool to elucidate molecular mechanisms mediating acceptance or failure of 
corneal graft. The model could be used to assess the potential of therapeutic molecules to enhance graft survival in vivo.
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BACKGROUND
Cornea is an avascular tissue and serves as a model system of 
choice for angiogenesis studies [1]. It actively works to establish an 
angiogenic privilege, which is essential for maintaining its transpar-
ency. Studies on corneal angiogenesis resulted in important insights 
into how angiogenesis is regulated, and in particular how blood and 
lymphatic neovessels can be inhibited or induced. Such studies led to 
the development of potential therapeutics for cardiovascular, neoplastic, 
and inflammatory diseases [2].
Studying cornea angiogenesis (hemangiogensis and/or lymphan-
giogenesis) provides a platform for exploring different aspects of the 
immune response [3]. It is known that a foreign antigen is brought to 
regional lymphatic tissue via lymphatic vessels where it is specifically 
recognized. While lymphatic vessels act as afferent arm of the immune 
response, blood vessels deliver the effector immune cells to the site 
of insult, acting as efferent arm of the immune response [4]. Aberrant 
growth of these vessels in the cornea breaks its immune privilege [5]. 
The link between angiogenesis and immune system in the cornea is 
bidirectional because resident immune cells play a critical role in ini-
tiating and promoting angiogenesis.
Several approaches, involving the eye, have been applied to in-
vestigate different aspects of angiogenesis and immunity. A landmark 
discovery in oncology, showing the tumor-mediated angiogenesis, 
emerged from introducing tumors into the anterior chamber of a rabbit 
eye [6]. Experimental eye models have been used to study allergic 
reactions to antigens [7] as well. Further it has been used to study 
cellular mechanisms that actively suppress immune responses such 
as melanocyte-stimulating hormone mediated immune regulation [8].
Our model allows for a comparative analysis of immune responses 
and the interplay between these responses and angiogenesis. It involves 
transplantation in an immune privilege context and non-immune priv-
ilege one by controlled induction of neovascularization [9]. Corneal 
transplantation is a common and clinically relevant way for studying 
the immune response to foreign antigens. The strength of our approach 
lies in its simplicity and cost effectiveness. An important advantage of 
corneal transplantation as a model is its accessibility and consequent 
ease of assessment for angiogenesis and immunological reaction. Since 
the original development of this model in early 90's [10, 11], our group 
along with others has been using this or adapted versions of the model 
to explore corneal immunity and angiogenesis for decades [9]. These 
efforts led to mechanistic understanding of immune tolerance and of 
secondary lymphangiogenesis [9].
Briefly, our protocol involves inducing inflammation and neovascular-
ization in cornea and using it as a host bed for corneal transplant. Inflamed 
and neovascularized host beds carry a higher risk of graft rejection [9]. 
Neovascularization and inflammation is achieved by performing three 
butterfly intra-stromal corneal sutures in a well-defined arrangement. 
After at least two weeks, to have a proper and stable neovascularization, 
we graft an allogeneic cornea onto the high-risk bed [12]. We can then 
monitor the graft and perform in vivo and ex vivo assessments.
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MATERIALS
Reagents
Male 6- to 8-week-old C57BL/6 mice are used as donors. Male 
6- to 8-week-old Balb/c mice are used as allogeneic recipients. We 
recommend usage of age- and sex-matched mice to have less variable 
outcomes. Depending on the aim of the study, the technique can be 
applied to different strains, genders, ages and animal models for donor 
and recipient animals. Care must be taken in trying different options as 
the ones recommended here. For example it is known that grafting on 
C57BL/6 mice induces a stronger immune reaction.
 9 Ocular viscoelastic device (OVD), (Bausch & Lomb, Rochester, 
NY, USA, Cat. # 59081L)
 9 Propacaine hydrochloride ophthalmic solution 0.5% (wt/vol), 
(Bausch & Lomb Incorporated, Tampa, FL, USA, NDC 24208-
730-06)
 9 Phenylephrine ophthalmic solution 5% (ALTAIRE Pharmaceuti-
cals, Inc., Aquebogue, NY, USA, NDC 59390-193-13)
 9 Tropicamide ophthalmic solution 1% (Bausch & Lomb Incorpo-
rated, Tampa, FL, USA, NDC 24208-590-64)
 9 Triple antibiotic eye ointment (Bacitracine Zinc, Neomycin, 
polymyxin B Sulfates), (Bausch & Lomb Incorporated, Tampa, 
FL, USA, NDC 24208-780-55)
 9 Ketamine (20 mg/kg)/Xylazine (100-200 mg/kg)
 9 Buprenorphine (0.05-0.1 mg/kg)
 9 Sterile Phosphate Buffer Saline (PBS), (Life Technologies Cor-
poration, Grand Island, NY, USA, Cat. # 10010-031)
Equipment
 9 11-0 nylon suture (MANI, Inc., Tochigi, Japan, Cat. # 0550S)
 9 8-0 nylon suture (MANI, Inc., Tochigi, Japan, Cat. # 2056)
 9 Sterile Jeweler’s forceps (one blunt and one fine)
 9 Scissors (Vannas and curved)
 9 Sterile trephine, diameter 2 mm and 1.5 mm. (HealthLink, Jack-
sonville, FL, USA, Cat. # BP15, BP20)
 9 Sterile needles 25G and 30G
 9 Binocular microscope
 9 Slit lamp
 9 Eye spears (Beaver Visitec International, Inc., Waltham, MA, 
USA, Cat. # 008680)
PROCEDURE
All animal experiments conducted in this protocol were approved by the Institutional Animal Care and Use Committee of the Schepens Eye 
Research Institute.
High-risk model
A mouse model of corneal neovascularization will be prepared using corneal sutures:
1. Anesthetize mouse with intraperitoneal ketamine (120 mg/kg) and xylazine (20 mg/kg) using a 25G needle.
2. Place mouse in a laterally recumbent position for surgical dissecting microscope visualization.
3. Cut the whiskers and eye lashes to have a clean operating field.
4. Wash the ocular surface with PBS and dry it using a sterile sponge (eye spears).
5. Apply one drop of anesthetic proparacaine 0.5% to the corneal surface prior to starting the procedure. Wait 1–2 min.
6. Dry the ocular surface using eye spears without touching the cornea.
7. Mark the central cornea with 1.5 mm trephine by softly touching the epithelium (Fig. 1A and 1B, Fig. 3A).
8. Place three intrastromal butterfly interrupted sutures (11-0 nylon) with two stromal incursions per suture, extending 
over 120° of the corneal circumference each. The sutures are positioned out of the marked area without reaching 
the limbus (Fig. 1C and 1D, Fig. 3B, Movie S1).
9. Apply antibiotic ointment.
10. Administer buprenorphine by subcutaneous injection through 25G needle immediately after surgery and every 12 
h for 48 h to minimize post-operative pain.
11. The mice will be clinically evaluated under a surgical microscope and slit lamp every day for up to 2 weeks.
Allogeneic penetrating corneal transplantation
First, prepare the donor cornea and then operate on the recipient.
Donor preparation
12. Euthanize donor mouse using CO2.
13. Mark the central cornea with a 2 mm diameter trephine. Here, we recommend applying enough pressure to pene-
trate into deep stroma without perforating the cornea.
14. Tunnel into the anterior chamber from a point on the marked edge using a 30G needle. A proper tunneling would 
lead to leakage of aqueous humor and a partial collapse of the anterior chamber.
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15. Inject OVD to rebuild the depth of the anterior chamber.
16. Carefully dry the surface with eye spears.
17. Partially excise the central donor cornea with Vannas scissors along the marked edge for 270 degrees (Fig. 2A).
18. For less experienced hands we recommend to pass the suture through the free edge of the donor cornea. This is a 
critical step because suturing the donor on the recipient may be difficult otherwise.
19. Excise the complete cornea, while the suture is in place, by cutting the remaining attachment.
20. Rapidly transfer the cornea with suture into sterile PBS and keep it until the recipient bed is prepared.
Recipient preparation
21. Anesthetize mouse with intraperitoneal ketamine (120 mg/kg) and xylazine (20 mg/kg) using a 25G needle.
22. Place mouse in a laterally recumbent position for surgical dissecting microscope visualization.
23. Cut the whiskers and eye lashes to have a clean operating field.
24. Wash the ocular surface with PBS and dry it using a sterile sponge (eye spears).
25. Apply one drop of anesthetic proparacaine 0.5% to the corneal surface prior to starting the procedure. Wait 1–2 min.
26. Apply one drop of phenylephrine and tropicamide each to dilate the pupil. Wait 1–2 min.
27. Dry the ocular surface using eye spears without touching the cornea.
28. Remove the intrastromal sutures (Movie S2).
29. Mark the central cornea with a 1.5 mm diameter trephine. In this case, we recommend applying enough pressure 
to penetrate into deep stroma without perforating the cornea (Fig. 3D, Movie S3).
30. Tunnel into the anterior chamber from the marked edge using a 30G needle. A proper tunneling would lead to 
leakage of aqueous humor and a partial collapse of the anterior chamber. Particular care should be taken to avoid 
touching lens and iris.
31. Inject OVD to rebuild the depth of the anterior chamber.
32. Carefully dry the surface with eye spears.
33. Excise the complete central host cornea with Vannas scissors along the marked edge (Movie S3).
34. Secure the 2.0 mm diameter donor cornea button to the prepared recipient bed of 1.5 mm diameter with 8 inter-
rupted 11–0 nylon sutures to keep a deep anterior chamber (Fig. 2C, 2D, Fig. 3E, Movie S4).
35. Inject OVD into anterior chamber during the procedure to maintain intraocular structure. We strongly recommend 
injecting OVD after placement of the first four sutures.
36. Wash the anterior chamber with PBS to remove OVD at the end of the procedure.
37. Keep the contralateral eye moist by using triple antibiotic ointment during the procedure.
38. Apply antibiotic ointment to the operated eye.
39. Close the eyelid for 24 h with 8-0 nylon sutures (tarsorrhaphy, avoids contact between sutures and orb).
40. Administer buprenorphine (0.05–0.1 mg/kg) by subcutaneous injections with a 25G needle immediately after 
surgery and every 12 h for 48 h to minimize post-operative pain.
41. Remove the eyelid sutures at 24 h post-transplantation in anesthetized recipients under a dissecting microscope 
with needles.
42. Remove 8 interrupted 11-0 nylon sutures at day 7 post transplantation.
Clinical assessment
Examine all grafted eyes using a slit lamp microscopy, and exclude 
grafts with technical difficulties (hyphema, infection, loss of anterior 
chamber). Examine grafts weekly by slit-lamp microscopy for edema, 
opacity, and neovascularization. Use a standard scoring system [13] 
(see Table 1) to describe the extent of opacity and neovascularization. 
Grafts with an opacity score of 2+ or greater 3 weeks after transplantation 
are considered rejected (immunologic failure). Grafts with an opacity 
score of 3+ or greater at 2 weeks post-transplantation that never clear 
are also considered rejected.
ANTICIPATED RESULTS
Introducing intrastromal sutures as described here will lead to growth 
of sprouting vessels within 1 to 2 days. Within few days a prominent 
neovascularization should be established in more than two quadrants 
of the cornea, which is minimally needed for an effective high-risk 
model (Fig. 2B, Fig. 3C).
Allogeneic corneal transplantation onto a vascularized and inflamed 
host bed, as described in our model, succeeds in 90% of the cases by the 
end of two weeks post transplantation. After 4 weeks, the graft survival 
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rate will decrease to 50% (Fig. 3F). In contrast, in the absence of inflam-
mation and aberrant vessels the rate of rejection is dramatically reduced 
and no grafts are rejected two weeks after transplantation [14, 15].
Figure 1. Intra-stromal suture placement. A and B. Marking the cornea. 
C. Suture positioning between the limbus and marked ring. D. Three 
butterfly sutures.
Figure 2. Allogenic corneal transplantation. A. Donor preparation. B. 
Vascularized and inflamed host bed. C. The graft after placement of four 
sutures. D. Allografted cornea.
Our model allows for detailed analysis of immune pathways in-
volved, including Th1 immune response, regulatory effect of T cells 
and pro-inflammatory and tolerogenic capacity of antigen presenting 
cells. We also use this model to study the role of innate and adaptive 
immunity in angiogenesis. All these are possible by not only using 
the eye tissues but also assessing the changes in the draining lymph 
node and spleen. Moreover, this model can be used with knockout and 
transgenic mice to evaluate various molecular pathways participating 
in immune response and angiogenesis.
A number of other models for high-risk corneal beds have been used 
previously and may complement the model proposed in this paper. The 
cornea micropocket assay [16] been used for such studies for decades; 
however, over time the assay has been replaced by the surgical pro-
cedure described in our paper which may has many advantages such 
as reproducibility, low cost, and easy feasibility. In the micropocket 
assay, the vessels are induced by a not discriminated combination of 
injury and drugs, and the success of the micropocket technique highly 
depends on the ability of the surgeon. Slight changes in the procedure and 
device inserted into the eye can result in very high variations of vessel 
induction. In contrast, using the suture model presented in this protocol 
induces homogenously distributed neovessels in all four quadrants of 
the cornea. We note that the model presented here does not serve as 
a generic model for all high-risk settings. For instance, patients with 
allergic background carry high risk for rejection. Here, we recommend 
usage of allergic mouse models [7]. Alkali burns to murine cornea also 
serve as suitable model systems for patients with accidental exposure 
to a number of chemicals [17]. Corneal alkali burn leads to severe 
neovascularization, however, the underlying damage to the cornea 
is biologically complex and we have limited control on the extent of 
the damages (in contrast to the suture model) that may involve limbal 
areas among others. Thus, it is relatively hard to disentangle the role 
of various contributing factors (immunologic and non-immunologic). 
Overall, the simplicity, availability, and the cost of the described model 
provide a unique platform to study basic principles of immunity and 
angiogenesis beyond ophthalmic issues.
TROUBLESHOOTING
During the procedure one may encounter a number of problems. Here 
we list potential issues and explain how one can do troubleshooting.
1. During introduction of intra-stromal sutures, one may occa-
sionally perforate the cornea. This is evidenced by leakage 
of the humor and a subsequent Siedel sign (Fig. 4). In this 
case, the immune privilege of the anterior chamber is com-
promised. The compromised cornea should be discharged.
2. Cataract is a major complication that results from touching 
the capsule of the lens while preparing the recipient. In this 
case, an undesired inflammatory reaction against the lens 
antigens will suddenly rise.
3. In case of incomplete removal of the OVD from the anterior 
chamber, we will face a high risk of intra ocular hypertension.
4. A severe complication is bleeding in the anterior chamber 
and subsequent hyphema formation. This is often related 
to cutting the iris during the procedure as well as to sudden 
decrease of the intraocular pressure during or after the pro-
cedure. Sometimes it can be caused by ingrowing neovessels 
into the anterior chamber after suture placement.
5. At the end of the procedure, it is important to check the 
tightness of the sutures and the arrangement of the graft 
edge for avoiding humor leakage and iris trap.
6. For phenylephrine administration, we suggest to administer 
the drug carefully to avoid airways and oral mucosa adsorp-
tion. Systemic adsorption of the drug leads to cardiovascular 
and respiratory dysfunctions.
7. Late removal of tarsorrhaphy may lead to surface inflam-
mation and an increased rejection rate.
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Figure 3. Schematic drawing of the surgical procedure. A. Mark the central cornea with 1.5 mm trephine. B. Place three intra-stromal butterfly in-
terrupted sutures. C. Vascularized and inflamed host bed. D. Mark the central donor cornea with 1.5 mm trephine. E. Donor cornea is transplanted onto 
vascularized cornea bed of the host. F. Rejected graft with vessel ingrowth and opacity.
Table 1. Graft scoring based on corneal opacity and neovascularization.
Score Clinical manifestations
0 Clear
1 Minimal superficial opacity, iris vessels readily visible
2 Minimal deep (stromal), opacity, iris vessels still visible
3 Moderate stromal opacity, only pupil margin visible
4 Intense stromal opacity, only portion of pupil margin visible
5 Maximal stromal opacity, anterior chamber not visible
Score Clinical manifestations
0 No vessels
1 Vessels bed only (1–2 quadrants)
2 Vessels bed only (3–4 quadrants)
3 Vessels recipient graft border (1–2 quadrants)
4 Vessels recipient graft border (3–4 quadrants)
5 Vessels peripheral donor stroma (1–2 quadrants)
6 Vessels peripheral donor stroma (3–4 quadrants)
7 Vessels central donor stroma (1–2 quadrants)
8 Vessels central donor stroma (3–4 quadrants)
Figure 4. Corneal perforation. Perforation is a main complication of 
intra-stromal suture placement. Positive Siedel sign.
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